Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 4/20 | 0.86 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.81 |
| ▸ | CHAT | P28329 | 2/20 | 0.78 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.78 |
| ▸ | AURKA | O14965 | 1/20 | 0.76 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.76 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26165784 | 0.94 | EP300 (0.88) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL17010823 | 0.92 | EP300 (0.86) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL30361785 | 0.91 | CHAT (0.85) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL20815907 | 0.91 | CHAT (0.85) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL1370748 | 0.91 | CHAT (0.85) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL30991360 | 0.91 | CHAT (0.85) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL14124932 | 0.90 | EP300 (0.85) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL30583329 | 0.90 | EP300 (0.82) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL21068032 | 0.90 | EP300 (0.82) | EP300KAT5CREBBPCHATNAA50 | |
| SCHEMBL1174543 | 0.90 | EP300 (0.82) | EP300KAT5CREBBPCHATNAA50 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | EP300 263/4885KAT5 647/4885CREBBP 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.